BRAF and thyroid gland carcinoma: A significant contribution to the definition of the molecular profile was offered in 2014 by the Thyroid Cancer Genome Atlas assessing that PTCs are either a BRAF V600E or a RAS-driven tumor and that these mutations are able to activate the mitogenic-activated protein kinase (MAPK) pathway (14).